Adaptimmune Therapeutics
ADAP
$1.19
Share price
-1.65%
Change (1 day)
-13.14%
Change (1 year)
Categories
Adaptimmune Therapeutics (ADAP) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $0.24 B
According to Adaptimmune Therapeutics's latest financial reports the company's total liabilities are $0.24 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Adaptimmune Therapeutics - Total liabilities on balance sheet (from 2014 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $0.24 B | -1.59% |
| 2022-12-31 | $0.24 B | -6.28% |
| 2021-12-31 | $0.26 B | 139.81% |
| 2020-12-31 | $0.10 B | 89.82% |
| 2019-12-31 | $57.9 M | 93.98% |
| 2018-12-31 | $29.85 M | -61.81% |
| 2017-12-31 | $78.16 M | 14.32% |
| 2016-12-31 | $68.37 M | |
| 2015-06-30 | $41.65 M | -21.58% |
| 2014-06-30 | $53.1 M | 1239.03% |
| 2013-06-30 | $3.96 M | -3.03% |
| 2012-06-30 | $4.09 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 uniQure QURE | $0.62 B | 156.69% | 🇳🇱 Netherlands |
 Novavax NVAX | $2.51 B | 934.30% | 🇺🇸 USA |
 Exelixis EXEL | $0.67 B | 179.08% | 🇺🇸 USA |
 Enzo Biochem ENZ | $28.3 M | -88.36% | 🇺🇸 USA |